DAWN News and Press, Day One Biopharmaceuticals Inc.

2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-07-07 06:58:14 ET Summary Today, we circle back to Day One Biopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April. Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging...

2024-06-18 13:13:38 ET More on Day One Biopharmaceuticals Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M Day One slips despite Ojemda approval as BofA says labe...

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- ...

FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application (NDA) meeting held Apr...

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare resource use for pediatric low-grade glioma care poster to be presented Company to host conference call and webcast on Sunday, ...

2023-04-25 09:21:10 ET Day One Biopharmaceuticals ( NASDAQ: DAWN ) lost ~14% pre-market Tuesday after Bank of America downgraded the clinical-stage biotech to Underperform from Buy, noting near-term negative catalysts for the stock. Bank of America expects the company to rel...

2023-04-25 09:04:56 ET TRACON Pharmaceuticals ( TCON ) -51% after I-Mab gets favorable ruling in arbitration. Appreciate Holdings ( SFR ) -26% . First Republic Bank ( FRC ) -22% after Q1 earning release . Netcapital ( NCPL ) -22% . T...

2023-04-20 09:00:52 ET Augmedix ( AUGX ) +91% a nnounces Partnership with HCA Healthcare to Accelerate the Development of AI-enabled Ambient Documentation. United Insurance Holdings  ( UIHC ) +32% . CNS Pharmaceuticals ( CNSP ) +28% . MDxHealth...